MDMA on track for 2023 approval as PTSD therapy, says developerA medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp Share XMDMA on track for 2023 approval as PTSD therapy, says developerhttps://pharmaphorum.com/news/mdma-on-track-for-2023-approval-as-ptsd-therapy-says-developer/
Magic mushroom compound matches antidepressant in clinical trialThe active compound in magic mushrooms – psilocybin – seems to be at least as effective as a Share XMagic mushroom compound matches antidepressant in clinical trialhttps://pharmaphorum.com/news/magic-mushroom-compound-matches-antidepressant-in-clinical-trial/
VC fund dedicated to psychedelic meds launches in UKIn the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – Share XVC fund dedicated to psychedelic meds launches in UKhttps://pharmaphorum.com/news/vc-fund-dedicated-to-psychedelic-meds-launches-in-uk/
Field Trip becomes latest psychedelic firm to go publicPsychedelic therapy company Field Trip Psychedelics has announced that it will soon join the growing list of psychedelic Share XField Trip becomes latest psychedelic firm to go publichttps://pharmaphorum.com/news/field-trip-becomes-latest-psychedelic-firm-to-go-public/
